{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-070348","form_type":"8-K","ticker":"PHGE","cik":"0001739174","company_name":"BiomX Inc.","filed_at":"2022-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.935164+00:00","generated_at":"2026-06-22T01:38:28.071926+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"BiomX Q3 net loss $6.8M; BX004 Part 1 results expected Q1 2023, cash through mid-2024","bullets":["Cash $41.5M as of Sep 30, 2022; cash runway through at least mid-2024.","Net loss $6.8M vs $10M in Q3 2021; R&D expenses $3.5M (down from $6.6M) due to restructuring.","BX004 Phase 1b/2a Part 1 results expected Q1 2023; Part 2 results Q3 2023.","CF Foundation equity award up to $5M; second $2M tranche upon Part 1 dosing completion.","Published Cell paper on phage proof-of-concept for inflammatory bowel disease."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-070348","json":"https://secwatch.observer/filing/0001213900-22-070348.json","markdown":"https://secwatch.observer/filing/0001213900-22-070348.md","text":"https://secwatch.observer/filing/0001213900-22-070348.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1739174/000121390022070348/0001213900-22-070348-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1739174/000121390022070348/ea168308-8k_biomx.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T01:38:28.071926+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1d6d34e93100a8068fdd9f46dd927bb30cc222c5","claim":"BiomX Inc. reported the third quarter ended September 30, 2022 results: net income $6.8 million.","evidence_excerpt":"Net loss for the third quarter of 2022 was $6.8 million, compared to $10 million for the same period in 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1739174/000121390022070348/0001213900-22-070348-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Net income","value":"$6.8 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}